The goal of this clinical trial is to compare buprenorphine formulations (sublingual buprenorphine versus long-acting injectable buprenorphine) for treating opioid use disorder among individuals who use fentanyl and/or other high potency synthetic opioids. Individuals aged 18-65 will be eligible for enrollment. The main questions it aims to answer are:
Are there differences in frequency of drug use after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine?
Are there differences in rates of sustained relapse after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine?
Investigators also seek to understand and explore:
How factors like body fat, body weight, and quantity of fentanyl use before treatment influence treatment outcomes.
How blood levels of buprenorphine and its metabolite norbuprenorphine early on in treatment may influence treatment outcomes.
How factors like craving and opioid withdrawal symptoms influence treatment outcomes.
Participants will:
Complete a brief overnight hospital stay in an inpatient research unit. This hospital stay will enable participants to start treatment with either sublingual buprenorphine or injectable buprenorphine.
Provide blood and urine samples while on the inpatient unit and at follow up.
Complete in-person follow up visits at 1-, 2-, 3- and 4-weeks after leaving the hospital to measure drug use, craving, withdrawal, quality of life, and physical health.

Start Date01 Aug 2026

Sponsor / Collaborator

National Institute on Drug Abuse

NCT06854029

/ Not yet recruitingPhase 4IIT

Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Start Date01 Jun 2026

Sponsor / Collaborator

Duke University

[+4]

NCT07176351

/ Not yet recruitingPhase 4IIT

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study

This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC).
Participants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.

Start Date01 Mar 2026

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Buprenorphine

100 Translational Medicine associated with Buprenorphine

100 Patents (Medical) associated with Buprenorphine

11,419

Literatures (Medical) associated with Buprenorphine

01 Dec 2026·Current Pain and Headache Reports

Perioperative Management of Patients on Buprenorphine

Review

Author: Mydlo, Nicholas ; Ng, Jessica ; Hines, Roberta ; Silverman, Matthew ; Hickey, Thomas ; Vadivelu, Nalini ; Kodumudi, Gopal ; Chowdhari, Sean ; Thomas, Donna-Ann ; Dextras, Christopher

PURPOSE OF THE REVIEW:

Our review discusses the pharmacologic profile of buprenorphine, then dives into the current literature regarding buprenorphine's use to treat chronic pain, opioid use disorder, and acute postoperative pain. We aim to focus on how that literature may influence the perioperative management of patients on buprenorphine and prompt reconsideration of buprenorphine as a frontline opioid analgesic.

RECENT FINDINGS:

Buprenorphine has been used effectively for both acute and chronic pain management, for the treatment of opioid withdrawal, and for the treatment of opioid use disorder due to its unique pharmacological profile. Historically, there has been controversy over the best practice recommendations for buprenorphine use in the perioperative setting, though the data now overwhelmingly refutes the full discontinuation of buprenorphine preoperatively. It has also been seen in recent times that buprenorphine is at least as effective as usual care opioids for acute pain management, with important safety advantages. Expanding our analgesic toolkit to more thoroughly understand the unique mechanism of action and properties of buprenorphine is paramount in our treatment of perioperative pain in both opioid-naïve and opioid-tolerant patients.

01 Jun 2026·Addictive behaviors reports

Influence of residential greenness and season on discontinuation of medication treatment for opioid use disorder across rural to urban community types

Article

Author: Bandeen-Roche, Karen ; Schwartz, Brian S ; Nordberg, Cara M ; DeWalle, Joseph ; Poulsen, Melissa N ; Berrettini, Wade

Introduction:

Medications for opioid use disorder (MOUD) are standard of care for opioid use disorder (OUD), but high rates of treatment discontinuation limit their impact on recovery. Nature exposure and engagement holds promise as a potential adjunctive treatment to MOUD through stress reduction and mental health benefits. This study evaluated whether nature exposure influenced MOUD treatment participation by analyzing associations of residential greenness with MOUD discontinuation across a diverse geography in Pennsylvania, while considering interrelated factors-season and community type.

Methods:

We analyzed electronic health records from 2,570 adults receiving MOUD from an outpatient addiction treatment program. Weekly MOUD participation was derived from medication days' supply of buprenorphine or naltrexone. Average weekly greenness (normalized difference vegetation index) was assigned to buffers surrounding participants' residential address. We applied mixed-effects logistic regression of pooled person-weeks in treatment to model the odds of MOUD discontinuation, clustered by patient and with robust standard errors.

Results:

In models adjusted for sociodemographic factors, residential greenness was not associated with MOUD discontinuation. We observed associations of season with MOUD discontinuation: compared to spring weeks, the odds of MOUD discontinuation were 20-27% higher during summer, fall, and winter weeks. In season-stratified models, we observed a non-linear association of greenness and MOUD discontinuation during the spring season.

Conclusions:

Understanding factors contributing to MOUD discontinuation is essential to improving recovery outcomes for those with OUD. Findings suggest that passive greenness exposure may have little influence on MOUD participation but identified the potential importance of season on MOUD outcomes.

01 Jun 2026·Journal of substance use and addiction treatment

The use of cellphone based automated pupillometry to quantify opioid withdrawal in patients receiving treatment for opioid use disorder

Article

Author: Washington, Wendy D ; Pond, Richard S ; Ludington, Jake D ; Van Leuven, Eric G ; Leli, Nathan B ; Chaney, Matthew W ; Vigilante, Kayla C ; MacQueen, David A ; Evonko, Christopher J

INTRODUCTION:

Overdose deaths attributed to opioid misuse resulted in over 50,000 deaths in 2024. Opioid agonist therapies such as methadone and buprenorphine are effective for the treatment of opioid use disorder (OUD). Yet, patient retention is an issue due to the challenges of stabilizing patients on an appropriate dose during the initial phase of treatment (induction). Accurate and objective quantification of opioid withdrawal can better optimize dose titration during induction. The study goal was to validate the use of cellphone-based pupillometry for assessing withdrawal in OUD.

METHODS:

Forty-five patients, currently engaged in methadone or buprenorphine treatment for OUD, were recruited from a local clinic. Participants were interviewed daily for fourteen consecutive days and reported on their drug use, their perceived craving and withdrawal (via the clinical opioid withdrawal scale (COWS) and completed an automated pupillary light reflex examination prior to receiving their daily dose. Pupillometry measures and self-reported craving and withdrawal measures were compared against time since last opioid dose (TSLD) to evaluate the sensitivity of measures to withdrawal. A multilevel modeling approach was conducted to account for the nested data.

RESULTS:

The pupillary light reflex was significantly associated with TSLD in those receiving methadone, and amongst those receiving high morphine equivalent doses. Opioid withdrawal as measured by the Clinical Opioid Withdrawal Scale (COWS) failed to demonstrate a significant relationship with TSLD.

CONCLUSIONS:

These findings suggest that pupillometry measures may be superior to commonly used self-report measures for assessing withdrawal in the context of MOUD for OUD.

124

News (Medical) associated with Buprenorphine

31 Mar 2026

·www.biospace.com

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

Model estimates SUBLOCADE ® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE ® , may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD). “Correctional facilities face ongoing staffing constraints as the need for MOUD continues to grow,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings highlight how monthly injectable buprenorphine can reduce dosing burden and staff involvement, enabling facilities to operate more efficiently while expanding access to evidence-based care.” The model compared staff time requirements across four MOUD options including methadone, oral buprenorphine, extended-release buprenorphine, and extended-release naltrexone, estimating monthly staffing needs and costs for treating 100 incarcerated patients with OUD. Using national mean wages and administration time estimates from literature, expert input, and manufacturer guidance, the model found: Reduced staff time : Monthly buprenorphine injections required fewer staff hours than other MOUD treatments—318 fewer staff hours vs. methadone; 747 fewer hours vs. oral buprenorphine; 192 hours fewer vs. weekly extended-release buprenorphine, and six hours fewer vs. extended-release naltrexone. Estimated cost savings : Reduced staff time translated to monthly cost savings ranging from $23 to $22,148, with largest savings stemming from the elimination of daily observed dosing and patient escorts. “Investing in more efficient MOUD delivery models can drive meaningful cost savings,” said Vanessa Procter, Executive Vice President of Corporate Affairs at Indivior. “Nearly half of U.S. jails and prisons cite staffing as a primary barrier to providing MOUD. LAIs can help expand access to evidence-based care while reducing operational burden, advancing shared public policy goals of improving health outcomes.” Study limitations include the exclusion of medication acquisition costs and some administration times and escorting procedures were based on assumptions in the absence of available data. Funded by Indivior, the study was conducted with Veradigm and researchers from the University of Kentucky College of Medicine. The full study findings are available here: Staffing Resource Use: Medications for Opioid Use Disorder Cost Impact Model in Carceral Facilities . About SUBLOCADE ® SUBLOCADE ® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse : SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression : Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions : Likelihood may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema, and pruritus with some involving abscess, ulceration, and necrosis. Neonatal Opioid Withdrawal Syndrome : Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency : If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation : If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events : Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids : Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain : Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit . About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit to learn more. Connect with Indivior on LinkedIn by visiting . For Further Information Investors: Jason Thompson Indivior Pharmaceuticals Tel: 804-402-7123 E-mail: jason.thompson@indivior.com Media: Cassie France-Kelly Indivior Pharmaceuticals Tel: 804-594-0836 E-mail: Indiviormediacontacts@indivior.com

Clinical Result

25 Mar 2026

·www.einpresswire.com

Integrity Treatment Partners Now Offers Monthly Sublocade and Vivitrol Injections for Opioid and Alcohol Addiction

Nassau County drug rehab now offers monthly Sublocade and Vivitrol injections for opioid and alcohol addiction on Long Island Monthly injections work great. Patients come in once a month, get their shot, and can focus on the rest of their treatment.” — Samantha Callister, Executive Director Integrity Treatment Partners NASSAU COUNTY, NY, UNITED STATES, March 25, 2026 / EINPresswire.com / -- BALDWIN, NY — March 2026 — Integrity Treatment Partners, a Joint Commission-accredited outpatient addiction treatment center in Nassau County, now administers Sublocade and Vivitrol injections on-site at its Baldwin office. Both medications are given once per month, removing the need for daily pills and reducing the risk of missed doses during recovery. Sublocade is a monthly buprenorphine injection that delivers steady medication levels for patients with opioid use disorder. Unlike daily Suboxone strips or tablets, Sublocade is injected into the abdomen once every 28 days, which eliminates the daily routine of taking medication and removes the possibility of diversion. The injection is administered by the clinic's medical team and takes approximately 15 minutes per visit. Patients searching for a Sublocade near me provider can schedule a same-day assessment through the clinic's 24/7 admissions line at (516) 200-1669. Vivitrol is a monthly naltrexone injection that blocks opioid and alcohol cravings without the risk of physical dependence. It works differently from buprenorphine-based medications — rather than activating opioid receptors at a low level, naltrexone blocks them entirely. This makes Vivitrol a preferred option for patients who have completed detox and want a medication that carries no addiction risk. For anyone looking for Vivitrol near me , the clinic can administer the injection and provide concurrent therapy and counseling at the same facility. Both medications are prescribed and supervised by Dr. Stuart Wasser, a board-certified addiction medicine physician with over 39 years of clinical experience. Dr. Wasser evaluates each patient individually to determine which medication is the best fit based on their substance use history, medical background, and treatment goals. "A lot of people struggle with taking medication every day, especially early in recovery," said Samantha Callister, LMSW, Executive Director of Integrity Treatment Partners. "Monthly injections take that variable off the table. Patients come in once, get their shot, and can focus on the rest of their treatment." In addition to Sublocade and Vivitrol, the clinic prescribes Suboxone (oral buprenorphine) and Brixadi, a newer injectable buprenorphine that is available in both weekly and monthly formulations. Having all four FDA-approved MAT medications available under one roof allows the medical team to adjust treatment plans without referring patients to outside providers. The clinic reports that patients on injectable medications show higher retention rates in outpatient programs compared to those on oral-only regimens. Monthly injections also simplify treatment for patients who are balancing work, school, or family obligations alongside their recovery. "Not every patient needs the same medication," said Dr. Stuart Wasser, Medical Director. "Having Suboxone, Sublocade, Vivitrol, and Brixadi all available here means we can match the treatment to the person, not the other way around." Integrity Treatment Partners is a licensed drug rehab on Long Island offering outpatient programs, intensive outpatient programs (IOP), and medication-assisted treatment. The clinic is located at 2250 Grand Ave, Baldwin, NY 11510 and serves patients from Nassau County, Suffolk County, Queens, and Westchester. Admissions are available 24/7 at (516) 200-1669 or at www.integritytreatmentpartners.com . Josh Goldfeder Integrity Treatment Partners +1 516-200-1669 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

20 Mar 2026

·www.drugs.com

Injectable, Extended-Release Buprenorphine Feasible for Opioid Use Disorder During Pregnancy

FRIDAY, March 20, 2026 -- Injectable, extended-release buprenorphine is safe and effective in pregnant women with opioid use disorder (OUD), according to a study published online March 16 in JAMA Internal Medicine . T. John Winhusen, Ph.D., from the University of Cincinnati, and colleagues evaluated the effectiveness and safety of extended-release buprenorphine versus sublingual buprenorphine for OUD in pregnancy through 12 months postpartum. The analysis included 140 adults with OUD and a singleton pregnancy of 6 to 30 weeks of gestational age seen at 13 outpatient cross-disciplinary peripartum OUD treatment sites. The researchers found that illicit opioid abstinence was higher during pregnancy for participants randomly assigned to extended-release versus sublingual buprenorphine (82.5 versus 72.6 percent). The groups were similar with respect to postpartum abstinence rates (60.2 versus 59.5 percent). There were fewer serious adverse events during pregnancy (8.7 versus 26.8 percent) and postpartum (6.0 versus 18.6 percent) among those receiving extended-release buprenorphine. There were more nonserious adverse events deemed medication-related for extended-release participants during pregnancy (26.1 versus 7.0 percent). Infants did not differ in the need for opioid treatment based on mothers' treatment assignment to extended-release versus sublingual buprenorphine (30.2 versus 26.5 percent; relative risk, 1.14; 98 percent confidence interval, 0.54 to 1.99; P = 0.64). "We knew that injectable extended-release buprenorphine leads to superior rates of illicit opioid abstinence in nonpregnant adults, but there had been no completed randomized clinical trial testing its use during pregnancy," Winhusen said in a statement. "It is exciting to share the results of this trial, which have immediate clinical application: this longer-acting medication can safely and more effectively support treatment and recovery in pregnant patients." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text

Clinical ResultClinical Study

100 Deals associated with Buprenorphine

External Link

KEGG	Wiki	ATC	Drug Bank
D07132	Buprenorphine	N07BC01	DB00921

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Opioid-Related Disorders	United States	Braeburn, Inc.	23 May 2023
Opium Dependence	European Union	Camurus AB	20 Nov 2018
Opium Dependence	Iceland	Camurus AB	20 Nov 2018
Opium Dependence	Liechtenstein	Camurus AB	20 Nov 2018
Opium Dependence	Norway	Camurus AB	20 Nov 2018
Opioid abuse	United States	Indivior, Inc.	30 Nov 2017
Pain	United States	Purdue Pharma LP	13 Oct 2017
Chronic Pain	United States	Purdue Pharma LP	30 Jun 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Analgesia	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Pain, Postoperative	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Intervertebral Disc Disease	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
Musculoskeletal Pain	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
opioid dependence methadone	Phase 3	United States	Titan Pharmaceuticals, Inc.	01 Sep 2008
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Osteoarthritis, Knee	Phase 3	United States	Purdue Pharma LP	01 Jun 1999
Low Back Pain	Phase 3	United States	Purdue Pharma LP	01 Apr 1997
Osteoarthritis	Phase 3	United States	Purdue Pharma LP	01 Nov 1996
Irritable Bowel Syndrome	Phase 2	United States	OrphoMed, Inc.	22 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04677114 (BOPAT, CTgov)	Phase 2	Opioid-Related Disorders \| Opioid abuse \| Infectious Diseases	71	care antibiotic treatment+Buprenorphine	trrbreiuhv = ugsnwslezc rwcdteazwm (ombtsllskd, cwdfwoqgfv - gixwgvewrj) View more	-	27 Mar 2026
NCT04225598 (Pubmed \| JAMA)	Phase 2	Opioid abuse	1,994	Extended-release buprenorphine	vwwmixrfbk(cfqlwanpcb) = awutvoegfs jepscwtavr (nvnabejznq ) View more	Similar	11 Feb 2026
				Sublingual buprenorphine	vwwmixrfbk(cfqlwanpcb) = uvsbrnwjzh jepscwtavr (nvnabejznq ) View more
NCT04995029 (CTgov)	Phase 4	Opioid-Related Disorders \| Opioid abuse	785	Extended-release Buprenorphine (Maintenance Phase: Extended-release Buprenorphine 100 mg)	dkajsgvorg = dnfmemvruw gngfavuotn (ophpiczorq, epwjklvbpp - mjfctlvtjr) View more	-	25 Sep 2025
				Extended-release Buprenorphine (Maintenance Phase: Extended-release Buprenorphine 300 mg)	dkajsgvorg = czrxcfftuy gngfavuotn (ophpiczorq, ihmrrxrngk - cvyydsmyko) View more
NCT04454411 (CTgov)	Phase 2	Opioid abuse \| Opium Dependence	3	Brixadi (Buprenorphine)	enletuqccq(cmzvkeieyq) = iwixxaprat asrfiqpnwu (prjfmmeoyf, awgalwrzed - iyxgevckls) View more	-	06 Aug 2025
				Vivitrol (Naltrexone)	enletuqccq(cmzvkeieyq) = vxarlpksqo asrfiqpnwu (prjfmmeoyf, benactijti - refgxnhbfa) View more
NCT04995029 (NEWS)	Phase 4	Opioid-Related Disorders	729	丁丙诺啡-RBP-6000	ykokeaohpu(cispgbqbcz) = oqoaclkylm loziomqvpa (blwhlksugh )	Superior	19 Nov 2024
				丁丙诺啡-RBP-6000（fentanyl-positive）	ykokeaohpu(cispgbqbcz) = ldcpzjjhxa loziomqvpa (blwhlksugh )
NCT02651584 (PRNewswire) Manual	Phase 3	Opioid-Related Disorders	123	BRIXADI (fentanyl-positive)	qxnxeftscw(lkignmzqwz) = hbgvaycnwt otfsfikqpx (vuotvvbgch ) View more	Positive	25 Jun 2024
				buprenorphine + naloxone (fentanyl-positive)	qxnxeftscw(lkignmzqwz) = gmalkodgkl otfsfikqpx (vuotvvbgch ) View more
NCT02651584 (Pubmed \| JAMA Netw Open)	Phase 3	fentanyl-positive \| norfentanyl	428	Subcutaneous Buprenorphine	jinmhvlzsg(hqtqtafakp) = zcvatllmea jseylcxvwo (pmrhiajhpg )	Positive	03 Jun 2024
				Sublingual Buprenorphine-Naloxone	jinmhvlzsg(hqtqtafakp) = ebbzidxzwc jseylcxvwo (pmrhiajhpg )
NCT02357901 \| NCT02510014 \| NCT02896296 (phase 3 studies, Pubmed \| J Subst Use Addict Treat)	Phase 3	Opioid abuse	916	BUP-XR 300 mg × 2	pzqjyvdrgh(mtnxkspyqh) = low incidence jqhmkdryqk (qvggttyjoq ) View more	Positive	01 Nov 2023
				BUP-XR 100 mg × 4
NCT02651584 (FDA) Manual	Phase 3	Opioid-Related Disorders	428	BRIXADI	rxqrxidokr(jzuurvddzp) = dknddqdabz wdqjpcksml (eqgoefyyvh ) View more	Positive	23 May 2023
				buprenorphine/naloxone	rxqrxidokr(jzuurvddzp) = yqcmyzrpka wdqjpcksml (eqgoefyyvh ) View more
NCT02611752 (FDA) Manual	Phase 2	Opioid-Related Disorders	47	BRIXADI	irxsfunocu(xsxajafgth) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo bkpfywpilv (luklgesimn )	Positive	23 May 2023
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis